⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Thiazolidinedione SCHEMBL135101 | 0.97 | — | — | |
| Thiazolidinedione SCHEMBL4895522 | 0.97 | — | — | |
| Thiazolidinedione SCHEMBL5043 | 0.97 | — | — | |
| Thiazolidinedione SCHEMBL4828229 | 0.97 | GSK3A (1.00) | — | |
| Thiazolidinedione SCHEMBL7844590 | 0.94 | — | — | |
| Thiazolidinedione SCHEMBL2331779 | 0.94 | — | — | |
| Thiazolidinedione SCHEMBL3294959 | 0.94 | — | — | |
| Thiazolidinedione SCHEMBL5795315 | 0.94 | — | — | |
| Thiazolidinedione SCHEMBL3294955 | 0.94 | — | — | |
| Thiazolidinedione SCHEMBL8522420 | 0.92 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11767317-B1 | Methods of synthesizing enantiopure deuterium-enriched pioglitazone | POXEL SA (FR) | 2023-09-26 | — | — | US | claimed |
| EP-4285900-B1 | CRYSTALLINE FORMS OF DEUTERIUM-ENRICHED PIOGLITAZONE | POXEL SA (FR) | 2025-06-11 | — | — | EP | disclosed |
| EP-4285900-A2 | CRYSTALLINE FORMS OF DEUTERIUM-ENRICHED PIOGLITAZONE | Poxel SA (FR) | 2023-12-06 | — | — | EP | disclosed |
| EP-4003514-B1 | CRYSTALLINE FORMS OF DEUTERIUM-ENRICHED PIOGLITAZONE | POXEL SA (FR) | 2023-10-04 | — | — | EP | disclosed |
| US-11767317-B1 | Methods of synthesizing enantiopure deuterium-enriched pioglitazone | POXEL SA (FR) | 2023-09-26 | — | — | US | disclosed |
| US-20230074827-A1 | CRYSTALLINE FORMS OF DEUTERIUM-ENRICHED PIOGLITAZONE | POXEL SA (FR) | 2023-03-09 | — | — | US | disclosed |
| EP-4003514-A1 | CRYSTALLINE FORMS OF DEUTERIUM-ENRICHED PIOGLITAZONE | Poxel SA (FR) | 2022-06-01 | — | — | EP | disclosed |
| US-11319313-B2 | Crystalline forms of deuterium-enriched pioglitazone | POXEL SA (FR) | 2022-05-03 | — | — | US | disclosed |
| WO-2022003426-A1 | CRYSTALLINE FORMS OF DEUTERIUM-ENRICHED PIOGLITAZONE | POXEL SA (FR) | 2022-01-06 | — | — | WO | disclosed |
| US-20210403464-A1 | CRYSTALLINE FORMS OF DEUTERIUM-ENRICHED PIOGLITAZONE | POXEL SA (FR) | 2021-12-30 | — | — | US | disclosed |
| EP-0749430-B1 | THIAZOLIDINEDIONE DERIVATIVES AS ANTI-HYPERGLYCEMIC AGENTS | AMERICAN HOME PROD (US) | 1999-08-25 | — | — | EP | disclosed |
| US-5605918-A | SUBSTITUTED THIAZOLIDINE-2,4-DIONES | AMERICAN HOME PRODUCTS CORPORATION (US) | 1997-02-25 | — | — | US | disclosed |
| EP-0749430-A1 | THIAZOLIDINEDIONE DERIVATIVES AS ANTI-HYPERGLYCEMIC AGENTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1996-12-27 | — | — | EP | disclosed |
| US-5574051-A | HYPOGLYCEMIC | AMERICAN HOME PRODUCTS CORPORATION (US) | 1996-11-12 | — | — | US | disclosed |
| US-5478851-A | Hyperglycemic agent and antilipemic agent | BEECHAM GROUP PLC (GB) | 1995-12-26 | — | — | US | disclosed |
| WO-1995024400-A1 | THIAZOLIDINEDIONE DERIVATIVES AS ANTI-HYPERGLYCEMIC AGENTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1995-09-14 | — | — | WO | disclosed |
| EP-0555251-A1 | THIAZOLIDINE DIONE DERIVATIVES | BEECHAM GROUP plc (GB) | 1993-08-18 | — | — | EP | disclosed |
| EP-0555264-A1 | NOVEL COMPOUNDS | BEECHAM GROUP plc (GB) | 1993-08-18 | — | — | EP | disclosed |
| WO-1992007850-A1 | NOVEL COMPOUNDS | BEECHAM GROUP PLC (GB) | 1992-05-14 | — | — | WO | disclosed |
| WO-1992007838-A1 | THIAZOLIDINE DIONE DERIVATIVES | BEECHAM GROUP PLC (GB) | 1992-05-14 | — | — | WO | disclosed |